FINANCIAL INSTRUMENTS

Short-term investments

Fair values were as follows:



	June 28, 2014								June 29, 2013
	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value		Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Estimated Fair Value
	(in thousands)
Available-for-sale investments
Government agency securities	$	—	$	—	$	—	$	—	$	25,024	$	36	$	—	$	25,060
U.S. treasury bills	49,853		100		—		49,953		—		—		—		—
Total available-for-sale investments	$	49,853	$	100	$	—	$	49,953	$	25,024	$	36	$	—	$	25,060

In the years ended June 28, 2014 and June 29, 2013, the Company did not recognize any impairment charges on short-term investments.

As of June 28, 2014, the U.S. treasury bills outstanding mature on May 15, 2016 and June 15, 2016.

Derivative instruments and hedging activities

The Company generates revenues in various global markets based on orders obtained in non-U.S. currencies, primarily the Japanese Yen, the Euro and the British Pound. The Company incurs expenditures denominated in non-U.S. currencies, including the Philippine Peso and Thai Baht associated with the Company's manufacturing activities in the Philippines and Thailand, respectively, and expenditures for sales offices and research and development activities undertaken outside of the U.S.

The Company has established a program that primarily utilizes foreign currency forward contracts to offset the risks associated with the effects of certain foreign currency exposures. The Company does not use these foreign currency forward contracts for trading purposes.

Derivatives designated as cash flow hedging instruments

The Company designates certain forward contracts as hedging instruments pursuant to ASC 815 Derivatives and Hedging. As of June 28, 2014 and June 29, 2013, respectively, the notional amounts of the forward contracts we held to purchase U.S. Dollars in exchange for other international currencies were $60.6 million and $53.8 million, respectively, and the notional amounts of forward contracts we held to sell U.S. Dollars in exchange for other international currencies were $0.8 million and $3.2 million, respectively.

Derivatives not designated as hedging instruments

As of June 28, 2014 and June 29, 2013, respectively, the notional amounts of the forward contracts we held to purchase U.S.

Dollars in exchange for other international currencies were $31.4 million and $15.0 million, respectively, and the notional amounts of forward contracts we held to sell U.S. Dollars in exchange for other international currencies were $48.9 million and $36.5 million, respectively. The fair values of our outstanding foreign currency forward contracts and amounts included in the Consolidated Statements of Income were not material for the years ended June 28, 2014 and June 29, 2013.

Long-term debt

The following table summarizes the Company's long-term debt:



	June 28, 2014			June 29, 2013
	(in thousands)
2.5% fixed rate notes due November 2018	$	500,000		$	—
3.375% fixed rate notes due March 2023	500,000			500,000
Notes denominated in Euro
Amortizing floating rate notes (EURIBOR plus 1.5%) due up to June 30, 2014	372			784
Term fixed rate notes (2.0%-2.5%) due up to September 2015	1,026			4,804
Total	1,001,398			505,588
Less: Current portion	(372		)	(2,015		)
Total long-term debt	$	1,001,026		$	503,573

On November 21, 2013, the Company completed a public offering of $500 million aggregate principal amount of the Company’s 2.5% coupon senior unsecured and unsubordinated notes due in November 2018 (“2018 Notes”), with an effective interest rate of 2.6%. Interest on the 2018 Notes is payable semi-annually in arrears on May 15 and November 15 of each year. The net proceeds of this offering were approximately $494.5 million, after issuing at a discount and deducting paid expenses, and are included in the financing activities in the Consolidated Statements of Cash Flows.

On March 18, 2013, the Company completed a public offering of $500 million aggregate principal amount of the Company's 3.375% senior unsecured and unsubordinated notes due in March 2023 (“2023 Notes”), with an effective interest rate of 3.5%. Interest on the 2023 Notes is payable semi-annually in arrears on March 15 and September 15 of each year. The net proceeds of this offering were approximately $490.0 million, after issuing at a discount and deducting paid expenses, and are included in the financing activities in the Consolidated Statement of Cash Flows.

The Company accounts for all the notes above based on their amortized cost. The discount and expenses are being amortized to Interest and other income (expense), net over the life of the notes. Interest expense associated with the notes was $24.7 million and $15.1 million during the years ended June 28, 2014 and June 29, 2013, respectively. The interest expense is recorded in Interest and other income (expense), net in the Consolidated Statements of Income.

The estimated fair value of the Company's debt was approximately $992 million as of June 28, 2014. The estimated fair value of the debt is based primarily on observable market inputs and is a Level 2 measurement.

The Company recorded interest expense of $27.0 million, $16.4 million, and $13.1 million during the years ended June 28, 2014, June 29, 2013, and June 29, 2013, respectively.

Credit Facility

The Company has access to a $350 million senior unsecured revolving credit facility with certain institutional lenders that expires on June 27, 2019. The facility fee is at a rate per annum that varies based on the Company's index debt rating and any advances under the credit agreement will accrue interest at a base rate plus a margin based on the Company's index debt rating. The credit agreement requires the Company to comply with certain covenants, including a requirement that the Company maintain a ratio of debt to EBITDA (earnings before interest, taxes, depreciation, and amortization) of not more than 3 to 1 and a minimum interest coverage ratio (EBITDA divided by interest expense) greater than 3.5 to 1. As of June 28, 2014, the Company had not borrowed any amounts from this credit facility and was in compliance with all debt covenants.

Other Financial Instruments

For the balance of the Company's financial instruments, cash equivalents, accounts receivable, accounts payable and other accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Impairment of investments in privately-held companies included in the consolidated statement of cash flows included an impairment of note receivable of $4.1 million and impairment of investments in preferred stock of $6.2 million.